This technology is a manufacturing method for obtaining a fermented brown rice product containing polysaccharides with a molecular weight of 1000 Da or less. It involves grinding and gelatinizing brown rice, followed by fermentation with the deposited strains Aspergillus oryzae SMF-138 and Rhizopus delemar SMF-136. The resulting product is formulated to improve lipid metabolism, lower blood sugar, and combat obesity.
Metabolic syndrome, characterized by the coexistence of obesity, insulin resistance, hyperlipidemia, and hypertension, significantly increases the risk of cardiovascular disease and diabetes. Often, lifestyle modifications alone are insufficient for improvement. Since statins, commonly used to lower lipids, carry risks of side effects, there is a demand for safe alternatives that can be consumed long-term as part of a daily diet.
This technology utilizes a complex fermentation process where two strains are sequentially cultured under staged temperature conditions to enhance vitality before being co-inoculated into brown rice, converting its components into easily absorbable low-molecular-weight polysaccharides. The fermented product improves lipid metabolism by lowering total blood cholesterol, LDL, and triglycerides. It can be applied to health functional foods for blood sugar and cholesterol management, meal-replacement grain products for metabolic syndrome, and fermented brown rice beverages, providing a daily-use lipid management material derived from brown rice that is less burdensome than statins.
This invention was developed with support from the Ministry of Agriculture, Food and Rural Affairs for the evaluation of the efficacy of fermented brown rice in improving glucose and lipid metabolism.
WO2015-170840A1